



# Publications 2007

## PEER REVIEWED

1. Chihota VN, Apers L, Mungofa S, Kasongo W, Streicher EM, Van Der Spuy GD, Victor T, Van Helden PD, Warren RM. Predominance of single genotype of *Mycobacterium tuberculosis* in regions of Southern Africa. *Int J Tuberc Lung Dis.* 2007; 11(3): 311-318.
2. Hallett TB, Gregson S, Lewis JJ, Lopman BA, Garnett GP. Behaviour change in generalized HIV epidemics: impact of reducing cross-generational sex and delaying age at sexual debut. *Sex Transm Infect.* 2007; 83 (Suppl 1): i50-54
3. Lewis JJ, Donnelly CA, Mare P, Mupambireyi Z, Garnett GP, Gregson S. Evaluating the proximate determinants framework for HIV infection in rural Zimbabwe. *Sex Transm Infect.* 2007; 83 (Suppl 1): i61-69.
4. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant A. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. *Int J Tuberc Lung Dis.* 2007 11(11): 1232-1236.
5. Churchyard GJ, Scano F, Grant AD, Chaisson RE. TB preventive therapy in the era of HIV infection: Overview and research priorities. *J Infect Dis.* 2007; 196 (Suppl. 1): S52-62.
6. Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV Coinfection: Current State of Knowledge and Research Priorities. *J Infect Dis.* 2007; 196 (Suppl 1): S1-3.
7. Weston M, Churchyard GJ, Mametja D, McIntyre J, Randerla F. Business and AIDS: Sectoral challenges and opportunities. *AIDS* 2007; 21 (Suppl 3): S85-89.
8. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L, Hamilton R, Grant A, Churchyard GJ. Evaluation of a Workplace HIV Treatment Programme in South Africa. *AIDS* 2007; 21(Suppl 3): S73-78.
9. Page-Shipp LS, Charalambous S, Roux S, Dias B, Sefuti C, Churchyard GJ, Grant AD. Attitudes to directly observed antiretroviral treatment in a workplace HIV care programme in South Africa. *Sex Transm Infect.* 2007; 83(5): 383-386.
10. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. *AIDS* 2007; 21(10): 1301-1308.
11. Babb DA, Pemba L, Seatlanyane P, Charalambous S, Churchyard GJ, Grant AD. Use of traditional medicine by HIV-infected individuals in South Africa in the era of antiretroviral therapy. *PsycholHealth Med.* 2007; 12(3): 314-320.
12. Churchyard GJ (Co-Author). Executive summary & recommendations from the WHO/UNAIDS/IAVI technical consultation on "Test of Concept / Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines", 31 January-2 February 2006, IAVI, New York, USA. *AIDS* 2007; 21(4): 539-546
13. Hallett TB, Lewis JJ, Lopman BA, Nyamukapa CA, Mushati P, Wambe M, Garnett GP, Gregson S. Age at first sex and HIV in rural Zimbabwe – trends and determinants. *Stud Fam Plann.* 2007; 38(1): 1-10.
14. Corbett EL, Bandason T, Cheung Y-B, Munyati SS, Godfrey-Faussett P, Hayes RJ, Churchyard GJ, Butterworth AE, Mason PR. Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with Enhanced Diagnosis of Symptomatic Disease. *PLoS Med.* Jan 2007 4(1) e22: 164-172
15. Peters BS, Jaoko W, Varda E, Panayotakopoulos G, Fast P, Schmidt C, Gilmour J, Bogoshi M, Omosa-Manyonyi G, Dally L, Klavinskis L, Farah B, Tarragona T, Bart PA, Robinson A, Pieterse C, Stevens W, Thomas R, Barin B, McMichael AJ, McIntyre JA, Pantaleo G, Hanke T, Bwayo J. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. *Vaccine.* 2007; 25(11): 2120-2127.
16. Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, Martin D, Wood R, Brink B, Churchyard GJ. Establishing a workplace antiretroviral therapy programme in South Africa. *AIDS Care.* 2007; 19(1):34-41

## NON-PEER REVIEWED

1. Churchyard GJ, Contributor. Good Practice Guidance on HIV/AIDS, Tuberculosis and Malaria. ICMM. Aug 2007. [www.erm.com](http://www.erm.com).
2. Churchyard GJ, Contributor. Guideline on isoniazid preventive therapy for patients with silicosis in South Africa. July 2007. [www.wahsa.net](http://www.wahsa.net).
3. Churchyard GJ, Levin, Wallis, Kaplan, Onyebujoh. Report of the expert consultation on immunotherapeutic interventions for TB. WHO/TDR Immunotherapy Report, Geneva, 29-31 January 2007.

## BOOK CHAPTERS

1. Hoffmann CJ, Churchyard G. Editors: Zumla A, Schaaf HS. Pulmonary Tuberculosis in Adults, A Clinical Treatise, 1st Ed. Elsevier. 2008.

## REPORTS

1. Debbie Muirhead, Andrew Van Zyl, Charles Hongoro, Moreblessing Chanakira, Gavin Churchyard, Lilani Kumaranayake, Charlotte Watts, Peter Vickerman, Gesine Meyer – Rath. Costs of HIV/AIDS to Anglo Group Companies: A Consolidated Picture – Intermediate Report of a Cost of Illness Assessment. Aurum Institute for Health Research. Internal Report.
2. Debbie Muirhead, Andrew Van Zyl, Charles Hongoro, Moreblessing Chanakira, Gavin Churchyard, Lilani Kumaranayake, Charlotte Watts, Peter Vickerman, Gesine Meyer – Rath. Costs of HIV/AIDS to Anglo Base Metals Companies: A Consolidated Picture – Intermediate Report of a Cost of Illness Assessment. Aurum Institute for Health Research. Internal Report.
3. Debbie Muirhead, Andrew Van Zyl, Gavin Churchyard, Lilani Kumaranayake. Costs of HIV/AIDS to Mondi: A Consolidated Picture – Intermediate Report of a Cost of Illness Assessment. Aurum Institute for Health Research. Internal Report.
4. Debbie Muirhead, Andrew Van Zyl, Charles Hongoro, Moreblessing Chanakira, Gavin Churchyard, Lilani Kumaranayake, Charlotte Watts, Peter Vickerman, Gesine Meyer – Rath. Costs of HIV/AIDS to Scaw Metals: A Consolidated Picture – Intermediate Report of a Cost of Illness Assessment. Aurum Institute for Health Research. Internal Report.
5. Andrew van Zyl. HIV Impact Analysis – Powertech Group of Companies. Internal Report.

## ABSTRACTS: CONFERENCES

### 38th IUATLD Conference, 8-12 November 2007, Cape Town, South Africa

1. Louw E, Churchyard G, Coetzee L. Quality management in a public health intervention.
2. Mngadi K, Churchyard G, Grant A, Coetzee L, Fielding K. Adverse event experience in workplace setting of wide-spread isoniazid preventive therapy.
3. Coetzee L, Louw E, Crawford T, Barnes G. Interpreting good clinical practice for a community study.

4. Popane F, Churchyard G, Coetzee L, Mngadi K. Eligibility criteria for IPT in a community-wide isoniazid prevention therapy study.
5. Coetzee L, Mngadi K, Luttig M, Popane F. Operational challenges implementing a community intervention in an industrial setting.
6. Chihota V, Poswa X, Fielding K, Molefe P, Pilane G, Lewis J, Coetzee L, Grant A, Churchyard G. A comparison of MGIT versus LJ culture by smear status in pulmonary TB in gold miners in South Africa.

***AIDS Vaccine Conference, Seattle, Washington, United States, August 2007***

7. Churchyard GJ, Keefer M, Morgan C, Adams E, Moodie Z, Graham B, Gu L, Hural J, McElrath MJ, Bekker LG, Gray G, Vardas E, and the NIAID HIV Vaccine Trials Network. Safety and Immunogenicity of the NIAID VRC Multiclade HIV-1 DNA plasmid / multiclade rAd5 Vector Vaccine (HVTN 204) in South African participants.
8. Keefer M, Morgan C, Churchyard GJ, Adams E, Hural J, Graham B, Moodie Z, Gray G, Bekker L-G, Baden L, McElrath J, and the NIAID HIV Vaccine Trials Network. A Phase IIA Trial to Evaluate a Multiclade HIV-1 DNA Vaccine Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in HIV-1 Uninfected Adults (HVTN 204).

***2007 HIV/AIDS Implementers Meeting, Kigali, Rwanda, 16-19 June 2007***

9. Pemba L, Monare E, Kruger P, Churchyard G, Innes C, Shisana M, Grant A, Fielding K. Early successes of a general practitioner model of ART delivery in South Africa. Oral Presentation. Abstract [990].
10. Puso TA, Charalambous S, Innes C, Seatlanyane P, Hamilton R, Dahab M, Churchyard G. Tracking of ART patients who are lost to follow-up in the workplace. Poster. Abstract [1260].

***3rd South African AIDS Conference, Durban, South Africa, 5-8 June 2007***

11. Innes C, Charalambous S, Pemba L, Bogoshi M, Whetham J, Seatlanyane P, Senoge S, Fielding K, Churchyard G, Grant A. Causes of mortality in patients on antiretroviral therapy in South Africa. Oral Presentation. Abstract [698].
12. Bogoshi M, Charalambous S, Pemba L, Whetham J, Innes C, Sefhuti C, Nielson T, Fielding K, Churchyard G, Grant A. Immune reconstitution inflammatory syndrome case definition in predominantly mine workers in South Africa. Oral Presentation. Oral Presentation. Abstract [832].

13. Van Zyl A, Muirhead D, Hongoro C, Chanakira M, Churchyard G. The value of preventing HIV infections in a workplace setting – a nine firm study in South Africa. Oral Presentation. Oral Presentation. Abstract [876].
14. Van Zyl A, Muirhead D, Hongoro C, Chanakira M, Kumaranayake L, Churchyard G. The determinants and composition of economic impact of HIV in ten South African firms. Poster. Abstract [845].
15. Frigati L, Hamilton R, Charalambous S, Pemba L, Churchyard G, Grant A. Attitudes to Disclosure of HIV status among HIV-infected individuals in a workplace setting: Perception of Healthcare Workers. Poster. Abstract [703].
16. Eisenstein M, Soldati Y, Charalambous S, Clark D. Feasibility of a digital pen and paper solution in an HIV treatment setting. Abstract [760].
17. Puso T, Charalambous S, Grant A, Hoffmann C, Moss A, Sim J, Churchyard G. HIV resistance after failure on the first-line regimen: prevalence and profiles. Poster. Abstract [849].
18. Dahab M, Hamilton R, Charalambous S, Makoa Z, Tsimele J, Fielding K, Churchyard G, Karstaedt A, Grant A. Belief in and use of traditional medicines among patients starting ART in South Africa. Poster. Abstract [857].
19. Wessie G, Bogoshi M, Jonkane J, Dhlamini B, Magcuntsu E, Sekhohola S. Lessons learnt in mobilizing communities for a vaccine trial in KOSH (Klerksdorp, Orkney, Stilfontein, Hartbeesfontein) in the North West Province. Poster. Abstract [829].
20. Ndiabongo B, Muirhead D, Letlape O, Innes C. Additional costs of side effect treatment in a private sector programme. Poster. Abstract [714].

***Other conferences***

21. Crawford T, Clark DA, Coetzee L. Data management in public health: CREATE – Thibela TB: A case study. Invited keynote speaker, Phase Forward European User Conference, 10 May 2007, London, UK.
22. Muirhead D. Exploring the impact of HIV/AIDS and its treatment on individual worker, team and firm level productivity in South Africa. Oral Presentation. iHEA Congress, Copenhagen, Denmark, July 2007.
23. Hamilton, R, Dwadwa, T, Charalambous, S, Mtshaki, J & Churchyard, G. Implementing a four-stage approach to adherence counselling for antiretroviral treatment using

the Egan counselling model. AIDS Impact Conference, Marseilles, France, 2-4 July 2007. Abstract [26.74].

24. Ntshele S. Mobilising communities for a public health intervention. EDCTP 4th Annual Forum. Burkina Faso, October 2007
25. Clark DA, Coetzee L. Public Health Programmes: Mobilising Communities: Thibela TB Case Study. Invited presentation, International Clinical Trials Symposium, Sydney, Australia, 25 September 2007
26. Churchyard GJ. TB control in HIV prevalent communities: experience from the South African gold mining industry and implications for TB vaccine development. Annual Thaler presentation. Aeras Global TB Vaccine Foundation. 17 August 2007. Washington, US
27. Grant AD. Isoniazid preventive therapy in an era of multi-drug resistant TB. invited speakers, 4th IAS conference, 22-25 July 2007, Sydney, Australia.
28. Churchyard GJ. Isoniazid preventive therapy for silica exposed workers. South African Thoracic Society conference, Cape Town. 2007.
29. Churchyard GJ. Preventing TB and opportunistic infections among HIV-infected adults. Combined SA / Royal College of Physicians meeting, Cape Town, 2007